厄贝沙坦治疗心房颤动的临床疗效及安全性评价

摘要

Objective To evaluate the treatment effect and security of irbesartan for patients with atrial fibrillation. Methods 118 patients with atrial fibrillation were randomly divided into observation group and control group equally.The control group was treated with anticoagulant and amiodarone (usage:first week dosage is 0.6 g/d, second week dosage is 0.4 g/d, after 2 weeks in order to maintain the level of 0.2 g/d to continue treatment), and the observation group was given anticoagulant and amiodarone plus irbesartan (usage:150 mg/d, 1 times a day), two groups of patients continuous medication for 6 months.All the patients were followed for one year, and then the changes of left atrial diameter before and after treatment,the clinical efficacy were compared between the two groups. Results the total efficiency of observation group was 94.91%(56/59), patients in the control group the total efficiency is 72.88%(43/59), the total efficiency of observation group was higher than that of control group (P<0.05). Before treatment, the observation group of patients withleft atrial diameter (45.3 ± 6.5) mm, the control group of patients with left atrial diameter (45.2 ±6.4) mm before treatment, no significant difference after treatment, the observation group of patients with left atrial diameter (36.7 ± 3.9) mm, the patients in the control group the left atrial diameter (42.9 ± 6.1) mm, there is significant difference after treatment (P<0.05). The incidence of adverse reactions in 5.1%, the control group adverse reaction rate was 15.3%, the observation group of patients with adverse reaction rate was significantly lower than that incontrol group (P<0.05). Conclusion The clinical treatment effect of irbesartan for patients with atrial fibrillation is outstanding.It can improve left atrial function and have less adverse reaction.%目的：评价厄贝沙坦治疗心房颤动（房颤）患者的临床疗效及安全性。方法选择118例房颤患者，将患者随机分为观察组和对照组，各59例。对照组患者给予抗凝治疗及胺碘酮治疗（用法：第1周用量0.6 g/d，第2周用量0.4 g/d，2周后以维持量0.2 g/d继续治疗），观察组在对照组的基础上给予厄贝沙坦治疗（用法：150 mg/(次·d)每天1次），2组患者均连续服药6个月。对所有患者进行为期1年的随访，比较2组患者的临床疗效、治疗前后左心房径的变化有无差别。结果观察者患者的总有效率是94.91%（56/59），对照组患者的总有效率是72.88%（43/59）,观察组患者的总有效率要明显高于对照组（P＜0.05）。治疗前，观察组患者的左心房径（45.3±6.5）mm，对照组患者的左心房径（45.2±6.4）mm，治疗前比较差异无统计学意义；治疗后，观察组患者的左心房径（36.7±3.9）mm，对照组患者的左心房径（42.9±6.1）mm，治疗后比较差异有统计学意义（P＜0.05）。观察组不良反应发生率5.08%,对照组不良反应发生率15.25%，观察组患者的不良反应发生率要明显低于对照组（P＜0.05）。结论厄贝沙坦治疗房颤的临床疗效显著，改善房颤患者左心房的功能，不良反应少。